Results 31 to 40 of about 507,262 (350)

Blended Heparin: A new Perspective to Guarantee the Supply of a Life-Saving Drug?

Clinical and Applied Thrombosis/Hemostasis, 2023
The risk of heparin shortage opens up the possibility of diversifying the sources of heparin by introducing products of other animal/organ origins. In addition to bovine heparin, already used in the past in the United States and Europe, ovine heparin can
Marco Guerrini MS
doaj   +1 more source

Heparin-induced thrombocytopenia: a rare presentation with skin necrosis

Dermatology Reports, 2023
Heparin-induced thrombocytopenia is the most clinically relevant non-haemorrhagic complication of heparin and is characterised by the presence of anti-PF4/heparin-IgG antibodies.
Filipa David, Ana Catarina Trigo, José Ribeiro, Joana Cancela   +3 more
doaj   +1 more source

Heparin resistance in COVID-19 patients in the intensive care unit

Journal of Thrombosis and Thrombolysis, 2020
Patients with COVID-19 have a coagulopathy and high thrombotic risk. In a cohort of 69 intensive care unit (ICU) patients we investigated for evidence of heparin resistance in those that have received therapeutic anticoagulation.
D. White, S. MacDonald, T. Bull, M. Hayman, R. D. Monteverde-Robb, D. Sapsford, A. Lavinio, J. Varley, A. Johnston, M. Besser, W. Thomas   +10 more
semanticscholar   +1 more source

Heparin modulates the endopeptidase activity of Leishmania mexicana cysteine protease cathepsin L-Like rCPB2.8 [PDF]

, 2013
Cysteine protease B is considered crucial for the survival and infectivity of the Leishmania in its human host. Several microorganism pathogens bind to the heparin-like glycosaminoglycans chains of proteoglycans at host-cell surface to promote their ...
Gesteira, Tarsis F., Tarsis F Gesteira, Gesteira Tarsis F., Sanya J Sanderson, Tersariol, Ivarne L.S., Westrop, Gareth, Sansevero, Thiago M., Shida, Claudio S. [UNIFESP], Manfredi, Marcella A, Tersariol, Ivarne Luis dos Santos [UNIFESP], Gerson P Souza, Ivarne L S Tersariol, Luiz Juliano, Manfredi Marcella A., Gareth D Westrop, Sansevero Thiago M., Almeida Paulo C., Tersariol Ivarne L. S., Souza, Gerson A., Manfredi, Marcella A., Sanderson Sanya J., Thiago M Sansevero, Souza, Gerson P., Juliano, Luiz, Westrop, Gareth D., Almeida, Paulo C. [UNIFESP], Judice, W.A.S., Paulo C Almeida, Judice Wagner A. S., Coombs Graham H., Coombs, Graham H., Shida, Claudio S., Shida Cláudio S., Cláudio S Shida, Souza Gerson P., Almeida, Paulo C, Judice, Wagner A. S., Marcella A Manfredi, Sanderson, Sanya J, Coombs, Graham, Juliano, Luiz [UNIFESP], Wagner A S Judice, Juliano Luiz, Sanderson, Sanya J., Graham H Coombs, Westrop Gareth D.   +45 more
core   +1 more source

An Ovarian Cancer Patient Presenting Heparin - Induced Thrombocytopenia after use of Low - Molecular - Weight Heparin: A Case Report of Rare Condition

Gynecology Obstetrics & Reproductive Medicine, 2019
Heparin-induced thrombocytopenia is a rare and life-threatening condition of exposure to heparin. A case of heparin-induced thrombocytopenia due to the low molecular weight heparin was presented.
Yasin Durmuş, Yalin Ay Karyal, Cigdem Kilic, Caner Cakir, Dilek Yuksel, Berna Seyhan, Gokhan Boyraz, Gunsu Kimyon Comert, Taner Turan   +8 more
doaj   +1 more source

Rivaroxaban Treatment for Heparin-Induced Thrombocytopenia: A Case Report and a Review of the Current Experience

Case Reports in Hematology, 2020
Heparin-induced thrombocytopenia is a life-threatening complication of exposure to heparin. Heparin-induced thrombocytopenia results from an autoantibody directed against platelet factor 4 in complex with heparin.
Mohamed Aon, Omar Al-Shammari
doaj   +1 more source

Graft-preserving intervention for treatment of heparin-induced thrombocytopenia secondary to a heparin-bonded renal artery bridging stent graft

Annals of Vascular Surgery - Brief Reports and Innovations, 2023
Heparin Induced Thrombocytopenia (HIT) is a well-recognized phenomenon in patients receiving heparin. Scoring systems such as the 4T score along with platelet factor 4 (PF4) testing have improved recognition and clinical improvement is typically observed
C.Y. Maximilian Png, John Schell, Alyssa M. Flores, Walter Dzik, Rebecca K. Leaf, Abhisekh Mohapatra   +5 more
doaj   +1 more source

Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients

EBioMedicine, 2020
Coronavirus disease-2019 (COVID-19) is associated with severe inflammation in mainly the lung, and kidney. Reports suggest a beneficial effect of the use of heparin/low molecular weight heparin (LMWH) on mortality in COVID-19.
Baranca Buijsers, Cansu Yanginlar, Marissa L. Maciej-Hulme, Q. de Mast, J. van der Vlag   +4 more
semanticscholar   +1 more source

Heparin és heparán-szulfát származékok, mint potenciális gyógyszerek [PDF]

, 2022
A dolgozatomban a heparin terápiás felhasználásait fejtettem ki részletesen. Dolgozatomat a heparin részletesebb bemutatásával és maga a hemosztázis rövid ismertetésével kezdtem.
Bodnár, Anikó
core  

Interactions between heparin and SARS-CoV-2 spike glycoprotein RBD from omicron and other variants

Frontiers in Molecular Biosciences, 2022
Heparan sulfate (HS) acts as a co-receptor of angiotensin-converting enzyme 2 (ACE2) by interacting with severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein (SGP) facilitating host cell entry of SARS-CoV-2 virus ...
Adrianne L. Gelbach, Fuming Zhang, Seok-Joon Kwon, John T. Bates, Andrew P. Farmer, Jonathan S. Dordick, Jonathan S. Dordick, Chunyu Wang, Chunyu Wang, Robert J. Linhardt, Robert J. Linhardt, Robert J. Linhardt   +11 more
doaj   +1 more source